MPLN vs. AMWL, AUGX, PHR, RVNC, NVRO, AVXL, NAUT, FBLG, TRML, and ACIU
Should you be buying MultiPlan stock or one of its competitors? The main competitors of MultiPlan include American Well (AMWL), Augmedix (AUGX), Phreesia (PHR), Revance Therapeutics (RVNC), Nevro (NVRO), Anavex Life Sciences (AVXL), Nautilus Biotechnology (NAUT), FibroBiologics (FBLG), Tourmaline Bio (TRML), and AC Immune (ACIU). These companies are all part of the "medical" sector.
MultiPlan (NYSE:MPLN) and American Well (NYSE:AMWL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
MultiPlan presently has a consensus price target of $2.00, indicating a potential upside of 239.39%. American Well has a consensus price target of $1.00, indicating a potential upside of 104.54%. Given MultiPlan's higher probable upside, analysts clearly believe MultiPlan is more favorable than American Well.
In the previous week, MultiPlan and MultiPlan both had 1 articles in the media. American Well's average media sentiment score of 0.42 beat MultiPlan's score of 0.00 indicating that American Well is being referred to more favorably in the news media.
MultiPlan has a net margin of -65.83% compared to American Well's net margin of -137.32%. MultiPlan's return on equity of -8.11% beat American Well's return on equity.
87.2% of MultiPlan shares are owned by institutional investors. Comparatively, 56.1% of American Well shares are owned by institutional investors. 8.2% of MultiPlan shares are owned by insiders. Comparatively, 12.9% of American Well shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
American Well received 22 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 47.76% of users gave American Well an outperform vote while only 41.67% of users gave MultiPlan an outperform vote.
MultiPlan has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, American Well has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
MultiPlan has higher revenue and earnings than American Well. MultiPlan is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.
Summary
MultiPlan beats American Well on 8 of the 15 factors compared between the two stocks.
Get MultiPlan News Delivered to You Automatically
Sign up to receive the latest news and ratings for MPLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MPLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MultiPlan Competitors List
Related Companies and Tools
